Posted by Michael Wonder on 11 Jan 2021
Organogenesis ReNu receives FDA regenerative medicine advanced therapy designation for osteoarthritis of the knee
11 January 2021 - FDA determines ReNu preliminary clinical evidence indicates potential to address unmet medical needs for the management of symptoms associated with knee osteoarthritis.
Organogenesis today announced that the U.S. FDA has granted ReNu, a cryopreserved amniotic suspension allograft for the management of symptoms associated with knee osteoarthritis, regenerative medicine advanced therapy designation.
